Emergent Biosolutions Stock Debt To Equity

EBS Stock

USD 9.23 0.09 0.97%

Fundamental analysis of Emergent Biosolutions allows traders to better anticipate movements in Emergent Biosolutions' stock price by examining its financial health and performance throughout various phases of its business cycle.

		Last Reported	Projected for Next Year
	Debt To Equity	1.37	1.44

Debt To Equity is likely to gain to 1.44 in 2025.

Build AI portfolio with Emergent Stock

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Emergent Biosolutions Company Debt To Equity Analysis

Emergent Biosolutions' Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.

D/E

Total Debt

Total Equity

More About Debt To Equity | All Equity Analysis

Current Emergent Biosolutions Debt To Equity

0.56 %

Most of Emergent Biosolutions' fundamental indicators, such as Debt To Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Emergent Biosolutions is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Emergent Debt To Equity Driver Correlations

Understanding the fundamental principles of building solid financial models for Emergent Biosolutions is extremely important. It helps to project a fair market value of Emergent Stock properly, considering its historical fundamentals such as Debt To Equity. Since Emergent Biosolutions' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Emergent Biosolutions' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Emergent Biosolutions' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Good Will	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock	Current Deferred Revenue	Long Term Debt	Short Term Investments	Property Plant Equipment	Deferred Long Term Liab	Treasury Stock	Net Tangible Assets	Long Term Debt Total	Capital Surpluse	Short Long Term Debt	Cash And Equivalents	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.94	0.67	0.45	0.6	0.62	0.63	0.96	0.64	0.48	0.69	0.64	0.72	0.8	0.74	0.96	0.72	-0.52	0.82	0.82	0.8	0.1	0.54	0.91	0.2	0.09
Total Stockholder Equity	0.94		0.4	0.54	0.45	0.53	0.41	0.81	0.55	0.33	0.48	0.42	0.74	0.67	0.55	0.97	0.57	-0.33	0.7	0.69	0.65	-0.09	0.62	0.83	0.37	0.17
Net Debt	0.67	0.4		-0.12	0.51	0.54	0.76	0.81	0.39	0.49	0.8	0.77	0.31	0.75	0.9	0.51	0.8	-0.77	0.74	0.74	0.83	0.41	-0.07	0.71	-0.28	-0.35
Retained Earnings	0.45	0.54	-0.12		0.59	0.5	0.3	0.34	0.73	0.22	0.37	0.26	0.53	0.1	-0.04	0.51	-0.03	0.22	0.12	0.17	-0.01	-0.21	0.8	0.43	0.41	0.61
Accounts Payable	0.6	0.45	0.51	0.59		0.81	0.86	0.66	0.91	0.3	0.85	0.83	0.7	0.54	0.6	0.45	0.47	-0.38	0.61	0.58	0.55	0.04	0.45	0.67	0.24	0.11
Net Receivables	0.62	0.53	0.54	0.5	0.81		0.85	0.64	0.72	0.02	0.84	0.81	0.7	0.68	0.62	0.5	0.47	-0.22	0.6	0.72	0.57	-0.33	0.17	0.59	0.39	0.12
Good Will	0.63	0.41	0.76	0.3	0.86	0.85		0.74	0.76	0.23	0.97	0.98	0.6	0.73	0.8	0.42	0.65	-0.49	0.73	0.77	0.72	0.08	0.14	0.65	0.16	-0.11
Total Liab	0.96	0.81	0.81	0.34	0.66	0.64	0.74		0.65	0.55	0.79	0.77	0.64	0.82	0.82	0.86	0.77	-0.62	0.85	0.85	0.84	0.23	0.44	0.89	0.06	0.03
Total Current Assets	0.64	0.55	0.39	0.73	0.91	0.72	0.76	0.65		0.41	0.75	0.74	0.67	0.47	0.49	0.57	0.43	-0.37	0.6	0.51	0.51	0.13	0.66	0.7	0.27	0.12
Short Term Debt	0.48	0.33	0.49	0.22	0.3	0.02	0.23	0.55	0.41		0.34	0.31	-0.05	0.03	0.28	0.49	0.27	-0.58	0.35	0.05	0.41	0.76	0.43	0.51	-0.65	0.16
Intangible Assets	0.69	0.48	0.8	0.37	0.85	0.84	0.97	0.79	0.75	0.34		0.94	0.56	0.73	0.8	0.51	0.66	-0.48	0.69	0.76	0.71	0.13	0.2	0.74	0.08	-0.06
Common Stock	0.64	0.42	0.77	0.26	0.83	0.81	0.98	0.77	0.74	0.31	0.94		0.57	0.7	0.82	0.45	0.67	-0.59	0.8	0.74	0.79	0.16	0.15	0.64	0.1	-0.1
Current Deferred Revenue	0.72	0.74	0.31	0.53	0.7	0.7	0.6	0.64	0.67	-0.05	0.56	0.57		0.72	0.57	0.66	0.52	-0.22	0.67	0.75	0.55	-0.3	0.52	0.68	0.69	0.04
Long Term Debt	0.8	0.67	0.75	0.1	0.54	0.68	0.73	0.82	0.47	0.03	0.73	0.7	0.72		0.88	0.67	0.84	-0.5	0.79	0.99	0.78	-0.06	0.14	0.77	0.38	-0.32
Short Term Investments	0.74	0.55	0.9	-0.04	0.6	0.62	0.8	0.82	0.49	0.28	0.8	0.82	0.57	0.88		0.59	0.87	-0.77	0.88	0.86	0.91	0.26	0.07	0.8	0.08	-0.45
Property Plant Equipment	0.96	0.97	0.51	0.51	0.45	0.5	0.42	0.86	0.57	0.49	0.51	0.45	0.66	0.67	0.59		0.63	-0.45	0.72	0.68	0.69	0.08	0.63	0.87	0.21	0.13
Deferred Long Term Liab	0.72	0.57	0.8	-0.03	0.47	0.47	0.65	0.77	0.43	0.27	0.66	0.67	0.52	0.84	0.87	0.63		-0.77	0.82	0.82	0.86	0.25	0.07	0.73	0.1	-0.43
Treasury Stock	-0.52	-0.33	-0.77	0.22	-0.38	-0.22	-0.49	-0.62	-0.37	-0.58	-0.48	-0.59	-0.22	-0.5	-0.77	-0.45	-0.77		-0.79	-0.46	-0.83	-0.65	-0.05	-0.6	0.31	0.5
Net Tangible Assets	0.82	0.7	0.74	0.12	0.61	0.6	0.73	0.85	0.6	0.35	0.69	0.8	0.67	0.79	0.88	0.72	0.82	-0.79		0.8	0.97	0.19	0.27	0.76	0.18	-0.24
Long Term Debt Total	0.82	0.69	0.74	0.17	0.58	0.72	0.77	0.85	0.51	0.05	0.76	0.74	0.75	0.99	0.86	0.68	0.82	-0.46	0.8		0.78	-0.09	0.19	0.76	0.4	-0.22
Capital Surpluse	0.8	0.65	0.83	-0.01	0.55	0.57	0.72	0.84	0.51	0.41	0.71	0.79	0.55	0.78	0.91	0.69	0.86	-0.83	0.97	0.78		0.25	0.12	0.75	0.01	-0.31
Short Long Term Debt	0.1	-0.09	0.41	-0.21	0.04	-0.33	0.08	0.23	0.13	0.76	0.13	0.16	-0.3	-0.06	0.26	0.08	0.25	-0.65	0.19	-0.09	0.25		0.14	0.27	-0.68	-0.35
Cash And Equivalents	0.54	0.62	-0.07	0.8	0.45	0.17	0.14	0.44	0.66	0.43	0.2	0.15	0.52	0.14	0.07	0.63	0.07	-0.05	0.27	0.19	0.12	0.14		0.56	0.32	0.38
Net Invested Capital	0.91	0.83	0.71	0.43	0.67	0.59	0.65	0.89	0.7	0.51	0.74	0.64	0.68	0.77	0.8	0.87	0.73	-0.6	0.76	0.76	0.75	0.27	0.56		0.15	-0.16
Net Working Capital	0.2	0.37	-0.28	0.41	0.24	0.39	0.16	0.06	0.27	-0.65	0.08	0.1	0.69	0.38	0.08	0.21	0.1	0.31	0.18	0.4	0.01	-0.68	0.32	0.15		0.05
Capital Stock	0.09	0.17	-0.35	0.61	0.11	0.12	-0.11	0.03	0.12	0.16	-0.06	-0.1	0.04	-0.32	-0.45	0.13	-0.43	0.5	-0.24	-0.22	-0.31	-0.35	0.38	-0.16	0.05

Click cells to compare fundamentals

High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.

Competition

Predict Emergent Biosolutions

Debt To Equity Over Time

Emergent Total Stockholder Equity

Total Stockholder Equity

617.99 Million

At this time, Emergent Biosolutions' Total Stockholder Equity is comparatively stable compared to the past year.

According to the company disclosure, Emergent Biosolutions has a Debt To Equity of 0.563%. This is 98.95% lower than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The debt to equity for all United States stocks is 98.84% higher than that of the company.

Emergent Debt To Equity Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Emergent Biosolutions' direct or indirect competition against its Debt To Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Emergent Biosolutions could also be used in its relative valuation, which is a method of valuing Emergent Biosolutions by comparing valuation metrics of similar companies.

Emergent Biosolutions is currently under evaluation in debt to equity category among its peers.

Emergent Biosolutions ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Emergent Biosolutions' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Emergent Biosolutions' managers, analysts, and investors.

Environmental

Governance

Social

Emergent Fundamentals

	Return On Equity	0.3
	Return On Asset	0.0503
	Profit Margin	0.16 %
	Operating Margin	0 %
	Current Valuation	892.93 M
	Shares Outstanding	53.35 M
	Shares Owned By Insiders	2.84 %
	Shares Owned By Institutions	70.03 %
	Number Of Shares Shorted	9.95 M
	Price To Earning	1.67 X
	Price To Book	0.92 X
	Price To Sales	0.58 X
	Revenue	1.01 B
	Gross Profit	480.2 M
	EBITDA	36.9 M
	Net Income	(190.6 M)
	Cash And Equivalents	99.5 M
	Cash Per Share	7.28 X
	Total Debt	663.7 M
	Debt To Equity	0.56 %
	Current Ratio	3.92 X
	Book Value Per Share	9.98 X
	Cash Flow From Operations	58.7 M
	Short Ratio	9.21 X
	Earnings Per Share	2.62 X
	Price To Earnings To Growth	1.55 X
	Target Price	13.5
	Number Of Employees	900
	Beta	1.98
	Market Capitalization	492.43 M
	Total Asset	1.39 B
	Retained Earnings	(212.4 M)
	Working Capital	436.3 M
	Current Asset	537.41 M
	Current Liabilities	99.61 M
	Net Asset	1.39 B

About Emergent Biosolutions Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Emergent Biosolutions's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Emergent Biosolutions using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Emergent Biosolutions based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Emergent Stock Analysis

When running Emergent Biosolutions' price analysis, check to measure Emergent Biosolutions' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Emergent Biosolutions is operating at the current time. Most of Emergent Biosolutions' value examination focuses on studying past and present price action to predict the probability of Emergent Biosolutions' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Emergent Biosolutions' price. Additionally, you may evaluate how the addition of Emergent Biosolutions to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2025 Macroaxis LLC